• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

用常规药物和补充剂来恢复当前 COVID-19 状况的次要方法。

A secondary approach with conventional medicines and supplements to recuperate current COVID-19 status.

机构信息

Faculty of Materials and Chemical Engineering, Yibin University, Yibin, Sichuan 644000, China.

School of Pharmacy, Xi'an Jiaotong University, Xi'an, Shaanxi 710061, China.

出版信息

Biomed Pharmacother. 2021 Oct;142:111956. doi: 10.1016/j.biopha.2021.111956. Epub 2021 Jul 27.

DOI:10.1016/j.biopha.2021.111956
PMID:34332377
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8313489/
Abstract

Novel coronavirus 2019 (COVID-19) is a zoonosis that revised the global economic and societal progress since early 2020. The SARS-CoV-2 has been recognized as the responsible pathogen for COVID-19 with high infection and mortality rate potential. It has spread in 192 countries and infected about 1.5% of the world population, and still, a proper therapeutic approach is not unveiled. COVID-19 indication starts with fever to shortness of breathing, leading to ICU admission with the ventilation support in severe conditions. Besides the symptomatic mainstay clinical therapeutic approach, only Remdesivir has been approved by the FDA. Several pharmaceutical companies claimed different vaccines with exceptionally high efficacy (90-95%) against COVID-19; how long these vaccines can protect and long-term safety with the new variants are unpredictable. After the worldwide spread of the COVID-19 pandemic, numerous clinical trials with different phases are being performed to find the most appropriate solution to this condition. Some of these trials with old FDA-approved drugs showed promising results. In this review, we have precisely compiled the efforts to curb the disease and discussed the clinical findings of Ivermectin, Doxycycline, Vitamin-D, Vitamin-C, Zinc, and cannabidiol and their combinations. Additionally, the correlation of these molecules on the prophylactic and diseased ministration against COVID-19 has been explored.

摘要

新型冠状病毒 2019(COVID-19)是一种动物源性传染病,自 2020 年初以来改变了全球经济和社会进程。SARS-CoV-2 已被确认为 COVID-19 的致病病原体,具有较高的感染和死亡率潜力。它已经在 192 个国家传播,感染了约 1.5%的世界人口,但仍未揭示出适当的治疗方法。COVID-19 的症状始于发热,继而出现呼吸急促,严重情况下需要入住 ICU 并进行通气支持。除了对症治疗的主要临床方法外,只有瑞德西韦已获得 FDA 的批准。几家制药公司声称针对 COVID-19 的不同疫苗具有极高的功效(90-95%);这些疫苗能保护多久,以及对新变体的长期安全性是不可预测的。COVID-19 大流行在全球范围内传播后,正在进行许多不同阶段的临床试验,以寻找治疗这种疾病的最佳方法。其中一些使用旧的 FDA 批准药物的试验显示出了有希望的结果。在这篇综述中,我们精确地汇编了控制疾病的努力,并讨论了伊维菌素、多西环素、维生素 D、维生素 C、锌和大麻二酚及其组合的临床发现。此外,还探讨了这些分子在 COVID-19 预防和疾病治疗中的相关性。

相似文献

1
A secondary approach with conventional medicines and supplements to recuperate current COVID-19 status.用常规药物和补充剂来恢复当前 COVID-19 状况的次要方法。
Biomed Pharmacother. 2021 Oct;142:111956. doi: 10.1016/j.biopha.2021.111956. Epub 2021 Jul 27.
2
Adjunctive Nutraceutical Therapies for COVID-19.辅助营养疗法治疗 COVID-19。
Int J Mol Sci. 2021 Feb 16;22(4):1963. doi: 10.3390/ijms22041963.
3
Multidrug treatment for COVID-19.COVID-19 的多药治疗。
Drug Discov Ther. 2021 Mar 10;15(1):39-41. doi: 10.5582/ddt.2021.01005. Epub 2021 Feb 19.
4
Effective Treatment of COVID-19 Infection with Repurposed Drugs: Case Reports.重新利用药物治疗 COVID-19 感染的疗效:病例报告。
Viral Immunol. 2024 Aug;37(6):298-307. doi: 10.1089/vim.2024.0034. Epub 2024 Aug 5.
5
Ivermectin for preventing and treating COVID-19.伊维菌素预防和治疗 COVID-19。
Cochrane Database Syst Rev. 2021 Jul 28;7(7):CD015017. doi: 10.1002/14651858.CD015017.pub2.
6
Combination Treatment With Remdesivir and Ivermectin Exerts Highly Synergistic and Potent Antiviral Activity Against Murine Coronavirus Infection.联合使用瑞德西韦和伊维菌素对小鼠冠状病毒感染具有高度协同和强大的抗病毒活性。
Front Cell Infect Microbiol. 2021 Jul 30;11:700502. doi: 10.3389/fcimb.2021.700502. eCollection 2021.
7
Identifying FDA-approved drugs with multimodal properties against COVID-19 using a data-driven approach and a lung organoid model of SARS-CoV-2 entry.采用数据驱动方法和 SARS-CoV-2 进入肺类器官模型鉴定具有针对 COVID-19 的多模态特性的 FDA 批准药物。
Mol Med. 2021 Sep 9;27(1):105. doi: 10.1186/s10020-021-00356-6.
8
Does Evidence Exist to Blunt Inflammatory Response by Nutraceutical Supplementation during COVID-19 Pandemic? An Overview of Systematic Reviews of Vitamin D, Vitamin C, Melatonin, and Zinc.在 COVID-19 大流行期间,营养补充剂是否有证据可以减轻炎症反应?对维生素 D、维生素 C、褪黑素和锌的系统评价综述。
Nutrients. 2021 Apr 12;13(4):1261. doi: 10.3390/nu13041261.
9
Drug Discovery of Small Molecules for the Treatment of COVID-19: A Review on Clinical Studies.小分子药物治疗 COVID-19 的发现:临床研究综述。
Mini Rev Med Chem. 2021;21(12):1431-1456. doi: 10.2174/1389557521666201228145755.
10
Repurposing Ivermectin for COVID-19: Molecular Aspects and Therapeutic Possibilities.将伊维菌素重新用于治疗新冠肺炎:分子层面及治疗可能性
Front Immunol. 2021 Mar 30;12:663586. doi: 10.3389/fimmu.2021.663586. eCollection 2021.

引用本文的文献

1
Unveiling the Interplay-Vitamin D and ACE-2 Molecular Interactions in Mitigating Complications and Deaths from SARS-CoV-2.揭示维生素D与血管紧张素转换酶2(ACE-2)的分子相互作用在减轻新冠病毒(SARS-CoV-2)并发症和死亡方面的作用
Biology (Basel). 2024 Oct 16;13(10):831. doi: 10.3390/biology13100831.
2
New insights from nanotechnology in SARS-CoV-2 detection, treatment strategy, and prevention.纳米技术在新冠病毒检测、治疗策略及预防方面的新见解。
Mater Today Chem. 2023 Apr;29:101478. doi: 10.1016/j.mtchem.2023.101478. Epub 2023 Mar 3.
3
Drug safety of frequently used drugs and substances for self-medication in COVID-19.

本文引用的文献

1
What scientists know about new, fast-spreading coronavirus variants.科学家们对新出现的、快速传播的新冠病毒变种的了解。
Nature. 2021 Jun;594(7861):19-20. doi: 10.1038/d41586-021-01390-4.
2
Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants.BNT162b2新冠疫苗对B.1.1.7和B.1.351变异株的有效性
N Engl J Med. 2021 Jul 8;385(2):187-189. doi: 10.1056/NEJMc2104974. Epub 2021 May 5.
3
Molecular Docking Reveals Ivermectin and Remdesivir as Potential Repurposed Drugs Against SARS-CoV-2.分子对接显示伊维菌素和瑞德西韦是针对新冠病毒的潜在重新利用药物。
新型冠状病毒肺炎(COVID-19)中常用的自我药疗药物和物质的药物安全性。
Ther Adv Drug Saf. 2022 Apr 21;13:20420986221094141. doi: 10.1177/20420986221094141. eCollection 2022.
4
A critical analysis of SARS-CoV-2 (COVID-19) complexities, emerging variants, and therapeutic interventions and vaccination strategies.对 SARS-CoV-2(COVID-19)复杂性、新兴变异体以及治疗干预和疫苗接种策略的批判性分析。
Biomed Pharmacother. 2022 Feb;146:112550. doi: 10.1016/j.biopha.2021.112550. Epub 2021 Dec 15.
Front Microbiol. 2021 Jan 25;11:592908. doi: 10.3389/fmicb.2020.592908. eCollection 2020.
4
Role of ivermectin in the prevention of SARS-CoV-2 infection among healthcare workers in India: A matched case-control study.伊维菌素在预防印度医护人员感染 SARS-CoV-2 中的作用:一项匹配病例对照研究。
PLoS One. 2021 Feb 16;16(2):e0247163. doi: 10.1371/journal.pone.0247163. eCollection 2021.
5
Understanding variants of SARS-CoV-2.了解严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的变种。
Lancet. 2021 Feb 6;397(10273):462. doi: 10.1016/S0140-6736(21)00298-1.
6
Modeling and forecasting the spread of COVID-19 with stochastic and deterministic approaches: Africa and Europe.运用随机和确定性方法对新冠疫情在非洲和欧洲的传播进行建模与预测
Adv Differ Equ. 2021;2021(1):57. doi: 10.1186/s13662-021-03213-2. Epub 2021 Jan 20.
7
Mechanism of SARS-CoV-2 polymerase stalling by remdesivir.瑞德西韦抑制 SARS-CoV-2 聚合酶的机制。
Nat Commun. 2021 Jan 12;12(1):279. doi: 10.1038/s41467-020-20542-0.
8
Potential effectiveness and adverse implications of repurposing doxycycline in COVID-19 treatment.多西环素在 COVID-19 治疗中的再利用的潜在效果和不良影响。
Expert Rev Anti Infect Ther. 2021 Aug;19(8):1001-1008. doi: 10.1080/14787210.2021.1865803. Epub 2020 Dec 24.
9
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.ChAdOx1 nCoV-19 疫苗(阿斯利康)对 SARS-CoV-2 的安全性和有效性:巴西、南非和英国四项随机对照试验的中期分析。
Lancet. 2021 Jan 9;397(10269):99-111. doi: 10.1016/S0140-6736(20)32661-1. Epub 2020 Dec 8.
10
A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness.一项为期五天的伊维菌素治疗 COVID-19 的疗程可能会缩短疾病的持续时间。
Int J Infect Dis. 2021 Feb;103:214-216. doi: 10.1016/j.ijid.2020.11.191. Epub 2020 Dec 2.